CRSP — CRISPR Therapeutics AG
$49.39-1.20%
Last close: · regular session
Last 60 sessions
CRSP closed at $49.39 (-1.20%) on Oct 23, 2026. Float: 78.4M shares. Latest SEC filing: SCHEDULE 13G/A on Aug 14, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for CRSP in the TickerWise workspace.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: CH
- Exchange: NASDAQ
- Employees: 393
- Website: https://www.crisprtx.com
Latest SEC filings for CRSP
Latest CRSP news
- CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know Read article
- Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know Read article
- CRISPR Therapeutics CFO steps down Read article
- Where Will CRISPR Therapeutics Stock Be in 2030? Read article
- Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock. Read article
- CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know Read article
- Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock Read article
- Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right. Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.